Greenwich LifeSciences (NASDAQ:GLSI) Posts Quarterly Earnings Results, Misses Estimates By $0.34 EPS

Greenwich LifeSciences (NASDAQ:GLSI) posted its quarterly earnings data on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.34), FiscalAI reports.

Greenwich LifeSciences Trading Up 8.9%

Shares of GLSI traded up $2.34 on Monday, reaching $28.51. 215,780 shares of the company’s stock were exchanged, compared to its average volume of 273,670. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10. The stock has a market capitalization of $394.86 million, a P/E ratio of -19.53 and a beta of 1.40. The business has a 50 day moving average price of $24.98 and a two-hundred day moving average price of $21.90.

Institutional Investors Weigh In On Greenwich LifeSciences

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Greenwich LifeSciences during the fourth quarter worth $217,000. Man Group plc bought a new stake in shares of Greenwich LifeSciences during the fourth quarter worth $590,000. Barclays PLC increased its position in shares of Greenwich LifeSciences by 11.8% during the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock worth $205,000 after acquiring an additional 1,030 shares in the last quarter. State Street Corp increased its position in shares of Greenwich LifeSciences by 19.3% during the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after acquiring an additional 15,831 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after acquiring an additional 4,102 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GLSI has been the topic of several recent research reports. Wall Street Zen upgraded shares of Greenwich LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $47.50.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.